Testing rectal mucus for colorectal cancer detection
Official title: Development of a Multiomics Assay for Use on OriColTM Sampled Rectal Mucus for Detection of Cancer and Significant Polyps in Symptomatic Patients on the Colorectal Urgent Suspected Cancer Pathway
Run by Origin Sciences · NCT06649123 · Data updated 2026-11-12
This study is testing a new way to use rectal mucus samples to see if it can help find colorectal cancer and important polyps in patients who need urgent cancer checks.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 6600 (estimated) |
| Sponsor | Origin Sciences Industry-sponsored |
| Locations | 1 site (Telford, Shropshire) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | April 1, 2026 |
| Study ends | April 1, 2027 |
| Registry record updated | April 4, 2025 |
| Trial ID | NCT06649123 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients aged 18 and over who have been referred to the urgent suspected cancer pathway for colorectal issues.
✕Probably not a fit
Patients with conditions that prevent a digital rectal examination or those currently pregnant may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to develop a multiomics assay using rectal mucus samples to detect colorectal cancer and significant polyps in patients referred for urgent cancer evaluation. It focuses on confirming and refining biomarker signatures related to colorectal cancer and high-risk adenomas, while also assessing the performance metrics of the Oricol™ test. Additionally, the study will evaluate the health economics of this diagnostic service compared to traditional pathways.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate detection of colorectal cancer and high-risk adenomas, improving patient outcomes.
How similar studies have gone: While similar approaches have been explored, this specific multiomics assay for rectal mucus is a novel application in the context of colorectal cancer detection.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients 18 years and over 2. Patients referred from primary care to the 'urgent suspected cancer' CRC pathway during the study period. 3. Patients who provide voluntary written informed consent to participate in the study. Exclusion Criteria: 1. Patients who are unable to undergo digital rectal examination (DRE). 2. Patients with peri-anal/anal symptoms that may limit DRE and proctoscopy examination and it would be clinically inappropriate to attempt to assess these patients. This may include conditions such as: * Patients who have undergone radiotherapy. * An acute or chronic anal fissure * Perianal haematoma * Acute thrombosed haemorrhoids * Post- operative anal stenosis * The presence of an obstructing anal/low rectal tumour or discomfort as a result of previous pelvic radiotherapy 3. Current pregnancy or suspicion of pregnancy.
Where it's running
-
Shrewsbury & Telford NHS Foundation Trust
Telford, Shropshire, United Kingdom Recruiting
Study contacts
- Study coordinator: Jon Lacy-Colson, FRCS
- Email: jon.lacy-colson@sath.nhs.uk
- Phone: +44(0)1743261000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy and machine learning to detect early colorectal cancer, advanced adenomas, Lynch-related cancers, and residual disease
This project will test a blood-based liquid biopsy that uses microRNA signals and machine learning to detect colorectal cancer, advanced adenomas, Lynch-associated cancers, and molecular residual disease in people who have a colonoscopy.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.